Skyrizi (risankizumab) - AbbVie, Boehringer Ingelheim
Skyrizi: Data from P3 trial for Crohn's disease in 2020 (AbbVie) - Feb 8, 2020 - Pipeline Update: Data from P3 KEEPSAKE2 trial (NCT03671148) for psoriatic arthritis in 2020 
P3 data
https://investors.abbvie.com/static-files/0f2e0201-ef33-432c-904e-8cf78d2d0929
 
Feb 8, 2020
 
 
c7fd0776-8fd7-4127-8e03-58d1c3bd7eeb.jpg